Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer

Summary

This study will evaluate the efficacy, safety and effect on quality of life of weekly paclitaxel plus bevacizumab as first line treatment in elderly patients (≥ 70 years old) with metastatic breast cancer. Furthermore, the efficacy of the combination therapy will be correlated with the functional status of patients according to the comprehensive geriatric assessment.

Timeline

Start

2009-09

Primary completion

2017-01

Completion

2017-01

Outcome

Outcome not reported

Stopped (Enrollment): “Due to poor accrual”

Drugs

Indications